Detalhe da pesquisa
1.
A survey of manufacturing and handling practices for monoclonal antibodies by pharmacy, nursing and medical personnel.
J Oncol Pharm Pract
; 22(2): 219-27, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25398311
2.
Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel.
Intern Med J
; 44(10): 1018-26, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25302720
3.
Feasibility of early discharge strategies for neutropenic fever: outcomes of a Victorian organisational readiness assessment and pilot.
Intern Med J
; 43(9): 979-86, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23809725
4.
Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee.
Intern Med J
; 41(1b): 102-9, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21272174
5.
The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset.
Intern Med J
; 41(1b): 121-9, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21272176
6.
Use of risk stratification to guide ambulatory management of neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.
Intern Med J
; 41(1b): 82-9, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21272172
7.
Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.
Intern Med J
; 41(1b): 90-101, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21272173
8.
Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee.
Intern Med J
; 41(1b): 75-81, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21272171
9.
An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009.
Intern Med J
; 41(1b): 110-20, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21272175
10.
Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes.
Int J Antimicrob Agents
; 47(5): 391-6, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27089829